Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Spectral karyotyping and SNP microarray analysis define uniparental disomy (UPD) as a novel mutational mechanism in MSI- and CSI-colorectal cancers.

Cellular oncology : the official journal of the International Society for Cellular Oncology

Melcher R, Zopf W, Hartmann E, Rosenwald A, Hoehn H, Schmid M, Kudlich T, Scheurlen M, Luehrs H.
PMID: 18936529
Cell Oncol. 2008;30(6):507. doi: 10.3233/clo-2008-0452.

No abstract available.

Cite
Melcher R, Zopf W, Hartmann E, et al. Spectral karyotyping and SNP microarray analysis define uniparental disomy (UPD) as a novel mutational mechanism in MSI- and CSI-colorectal cancers. Cell Oncol. 2008;30(6):507doi: 10.3233/clo-2008-0452.
Melcher, R., Zopf, W., Hartmann, E., Rosenwald, A., Hoehn, H., Schmid, M., Kudlich, T., Scheurlen, M., & Luehrs, H. (2008). Spectral karyotyping and SNP microarray analysis define uniparental disomy (UPD) as a novel mutational mechanism in MSI- and CSI-colorectal cancers. Cellular oncology : the official journal of the International Society for Cellular Oncology, 30(6), 507. https://doi.org/10.3233/clo-2008-0452
Melcher, Ralph, et al. "Spectral karyotyping and SNP microarray analysis define uniparental disomy (UPD) as a novel mutational mechanism in MSI- and CSI-colorectal cancers." Cellular oncology : the official journal of the International Society for Cellular Oncology vol. 30,6 (2008): 507. doi: https://doi.org/10.3233/clo-2008-0452
Melcher R, Zopf W, Hartmann E, Rosenwald A, Hoehn H, Schmid M, Kudlich T, Scheurlen M, Luehrs H. Spectral karyotyping and SNP microarray analysis define uniparental disomy (UPD) as a novel mutational mechanism in MSI- and CSI-colorectal cancers. Cell Oncol. 2008;30(6):507. doi: 10.3233/clo-2008-0452. PMID: 18936529; PMCID: PMC4618808.
Copy Download .nbib Format: NLM
Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [.

Diagnostics (Basel, Switzerland)

Weich A, Rogoll D, Gawlas S, Mayer L, Weich W, Pongracz J, Kudlich T, Meining A, Scheurlen M.
PMID: 33671498
Diagnostics (Basel). 2021 Feb 22;11(2). doi: 10.3390/diagnostics11020367.

Loss of Somatostatin Receptor 2 (SSTR2) expression and rising CXC Chemokine Receptor Type 4 (CXCR4) expression are associated with dedifferentiation in neuroendocrine tumors (NET). In NET, CXCR4 expression is associated with enhanced metastatic and invasive potential and worse prognosis...

Cite
Weich A, Rogoll D, Gawlas S, et al. Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [. Diagnostics (Basel). 2021;11(2)doi: 10.3390/diagnostics11020367.
Weich, A., Rogoll, D., Gawlas, S., Mayer, L., Weich, W., Pongracz, J., Kudlich, T., Meining, A., & Scheurlen, M. (2021). Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [. Diagnostics (Basel, Switzerland), 11(2), . https://doi.org/10.3390/diagnostics11020367
Weich, Alexander, et al. "Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [." Diagnostics (Basel, Switzerland) vol. 11,2 (2021). doi: https://doi.org/10.3390/diagnostics11020367
Weich A, Rogoll D, Gawlas S, Mayer L, Weich W, Pongracz J, Kudlich T, Meining A, Scheurlen M. Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [. Diagnostics (Basel). 2021 Feb 22;11(2). doi: 10.3390/diagnostics11020367. PMID: 33671498; PMCID: PMC7926465.
Copy Download .nbib Format: NLM
State-of-the-art surgery for Crohn's disease: Part I-small intestine/ileal disease.

Langenbeck's archives of surgery

Kavalukas SL, Scheurlen KM, Galandiuk S.
PMID: 34738167
Langenbecks Arch Surg. 2021 Nov 04; doi: 10.1007/s00423-021-02324-4. Epub 2021 Nov 04.

The management of Crohn's disease has evolved significantly over the past 20 years. The arrival of biologic therapies has altered not only the management and outcomes but also rates for refractory disease requiring surgery. New surgical techniques have paralleled...

Cite
Kavalukas SL, Scheurlen KM, Galandiuk S. State-of-the-art surgery for Crohn's disease: Part I-small intestine/ileal disease. Langenbecks Arch Surg. 2021;doi: 10.1007/s00423-021-02324-4.
Kavalukas, S. L., Scheurlen, K. M., & Galandiuk, S. (2021). State-of-the-art surgery for Crohn's disease: Part I-small intestine/ileal disease. Langenbeck's archives of surgery, . https://doi.org/10.1007/s00423-021-02324-4
Kavalukas, Sandra L, et al. "State-of-the-art surgery for Crohn's disease: Part I-small intestine/ileal disease." Langenbeck's archives of surgery vol. (2021). doi: https://doi.org/10.1007/s00423-021-02324-4
Kavalukas SL, Scheurlen KM, Galandiuk S. State-of-the-art surgery for Crohn's disease: Part I-small intestine/ileal disease. Langenbecks Arch Surg. 2021 Nov 04; doi: 10.1007/s00423-021-02324-4. Epub 2021 Nov 04. PMID: 34738167.
Copy Download .nbib Format: NLM
Itaconate and leptin affecting PPARγ in M2 macrophages: A potential link to early-onset colorectal cancer.

Surgery

Scheurlen KM, Snook DL, Walter MN, Cook CN, Fiechter CR, Pan J, Beal RJ, Galandiuk S.
PMID: 34876290
Surgery. 2021 Dec 04; doi: 10.1016/j.surg.2021.10.054. Epub 2021 Dec 04.

BACKGROUND: Along with the rising incidence of obesity, there has been an increase in patients diagnosed with early-onset colorectal cancer (

Cite
Scheurlen KM, Snook DL, Walter MN, et al. Itaconate and leptin affecting PPARγ in M2 macrophages: A potential link to early-onset colorectal cancer. Surgery. 2021;doi: 10.1016/j.surg.2021.10.054.
Scheurlen, K. M., Snook, D. L., Walter, M. N., Cook, C. N., Fiechter, C. R., Pan, J., Beal, R. J., & Galandiuk, S. (2021). Itaconate and leptin affecting PPARγ in M2 macrophages: A potential link to early-onset colorectal cancer. Surgery, . https://doi.org/10.1016/j.surg.2021.10.054
Scheurlen, Katharina M, et al. "Itaconate and leptin affecting PPARγ in M2 macrophages: A potential link to early-onset colorectal cancer." Surgery vol. (2021). doi: https://doi.org/10.1016/j.surg.2021.10.054
Scheurlen KM, Snook DL, Walter MN, Cook CN, Fiechter CR, Pan J, Beal RJ, Galandiuk S. Itaconate and leptin affecting PPARγ in M2 macrophages: A potential link to early-onset colorectal cancer. Surgery. 2021 Dec 04; doi: 10.1016/j.surg.2021.10.054. Epub 2021 Dec 04. PMID: 34876290.
Copy Download .nbib Format: NLM
Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence.

The Journal of surgical research

O'Brien SJ, Scheurlen K, Rochet A, Fiechter C, Paas M, Pan J, Rai SN, Galandiuk S.
PMID: 34520983
J Surg Res. 2021 Sep 11;269:59-68. doi: 10.1016/j.jss.2021.08.004. Epub 2021 Sep 11.

BACKGROUND: Colon cancer is a leading cause of cancer-related death. Long non-coding (Lnc) RNAs are critical mediators of tumor biology. H19 is a well-characterized lncRNA involved in p53 regulation and cancer progression. A specific colon cancer data set was...

Cite
O'Brien SJ, Scheurlen K, Rochet A, et al. Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. J Surg Res. 2021;269:59-68doi: 10.1016/j.jss.2021.08.004.
O'Brien, S. J., Scheurlen, K., Rochet, A., Fiechter, C., Paas, M., Pan, J., Rai, S. N., & Galandiuk, S. (2021). Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. The Journal of surgical research, 26959-68. https://doi.org/10.1016/j.jss.2021.08.004
O'Brien, Stephen J, et al. "Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence." The Journal of surgical research vol. 269 (2021): 59-68. doi: https://doi.org/10.1016/j.jss.2021.08.004
O'Brien SJ, Scheurlen K, Rochet A, Fiechter C, Paas M, Pan J, Rai SN, Galandiuk S. Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. J Surg Res. 2021 Sep 11;269:59-68. doi: 10.1016/j.jss.2021.08.004. Epub 2021 Sep 11. PMID: 34520983.
Copy Download .nbib Format: NLM
Comorbidities as an Indication for Metabolic Surgery.

Visceral medicine

Schwarz AC, Billeter AT, Scheurlen KM, Blüher M, Müller-Stich BP.
PMID: 30498706
Visc Med. 2018 Oct;34(5):381-387. doi: 10.1159/000493291. Epub 2018 Oct 28.

Metabolic diseases, comprising type 2 diabetes mellitus (T2DM), dyslipidemia, and non-alcoholic steatohepatitis (NASH), are rapidly increasing worldwide. Conservative medical therapy, including the newly available drugs, has only limited effects and does neither influence survival or the development of micro-...

Cite
Schwarz AC, Billeter AT, Scheurlen KM, et al. Comorbidities as an Indication for Metabolic Surgery. Visc Med. 2018;34(5):381-387doi: 10.1159/000493291.
Schwarz, A. C., Billeter, A. T., Scheurlen, K. M., Blüher, M., & Müller-Stich, B. P. (2018). Comorbidities as an Indication for Metabolic Surgery. Visceral medicine, 34(5), 381-387. https://doi.org/10.1159/000493291
Schwarz, Anne-Catherine, et al. "Comorbidities as an Indication for Metabolic Surgery." Visceral medicine vol. 34,5 (2018): 381-387. doi: https://doi.org/10.1159/000493291
Schwarz AC, Billeter AT, Scheurlen KM, Blüher M, Müller-Stich BP. Comorbidities as an Indication for Metabolic Surgery. Visc Med. 2018 Oct;34(5):381-387. doi: 10.1159/000493291. Epub 2018 Oct 28. PMID: 30498706; PMCID: PMC6257097.
Copy Download .nbib Format: NLM
CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas.

Diagnostics (Basel, Switzerland)

Weich A, Werner RA, Buck AK, Hartrampf PE, Serfling SE, Scheurlen M, Wester HJ, Meining A, Kircher S, Higuchi T, Pomper MG, Rowe SP, Lapa C, Kircher M.
PMID: 33805264
Diagnostics (Basel). 2021 Mar 29;11(4). doi: 10.3390/diagnostics11040605.

We aimed to elucidate the diagnostic potential of the C-X-C motif chemokine receptor 4 (CXCR4)-directed positron emission tomography (PET) tracer

Cite
Weich A, Werner RA, Buck AK, et al. CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics (Basel). 2021;11(4)doi: 10.3390/diagnostics11040605.
Weich, A., Werner, R. A., Buck, A. K., Hartrampf, P. E., Serfling, S. E., Scheurlen, M., Wester, H. J., Meining, A., Kircher, S., Higuchi, T., Pomper, M. G., Rowe, S. P., Lapa, C., & Kircher, M. (2021). CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics (Basel, Switzerland), 11(4), . https://doi.org/10.3390/diagnostics11040605
Weich, Alexander, et al. "CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas." Diagnostics (Basel, Switzerland) vol. 11,4 (2021). doi: https://doi.org/10.3390/diagnostics11040605
Weich A, Werner RA, Buck AK, Hartrampf PE, Serfling SE, Scheurlen M, Wester HJ, Meining A, Kircher S, Higuchi T, Pomper MG, Rowe SP, Lapa C, Kircher M. CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics (Basel). 2021 Mar 29;11(4). doi: 10.3390/diagnostics11040605. PMID: 33805264; PMCID: PMC8067200.
Copy Download .nbib Format: NLM
[Value of galactography for the diagnostic work-up of pathological nipple discharge in multimodal breast diagnostics : Part 1: An online survey among German breast care centers.].

Der Radiologe

Scheurlen K, Schnitzer A, Krammer J, Kaiser C, Schönberg SO, Wasser K.
PMID: 24233401
Radiologe. 2013 Nov 15; doi: 10.1007/s00117-013-2572-8. Epub 2013 Nov 15.

PURPOSE: Galactography has been used in cases of pathological discharge for decades. Meanwhile other methods, such as high-resolution ultrasound (US) and magnetic resonance mammography (MRM) have been established for modern multimodal breast imaging. A survey among certified German breast...

Cite
Scheurlen K, Schnitzer A, Krammer J, et al. Stellenwert der Galaktographie zur Abklärung pathologischer Sekretion in der komplementären Mammadiagnostik : Teil 1: Eine Onlineumfrage an den deutschen Brustzentren. [Value of galactography for the diagnostic work-up of pathological nipple discharge in multimodal breast diagnostics : Part 1: An online survey among German breast care centers.]. Radiologe. 2013;doi: 10.1007/s00117-013-2572-8.
Scheurlen, K., Schnitzer, A., Krammer, J., Kaiser, C., Schönberg, S. O., & Wasser, K. (2013). Stellenwert der Galaktographie zur Abklärung pathologischer Sekretion in der komplementären Mammadiagnostik : Teil 1: Eine Onlineumfrage an den deutschen Brustzentren. [Value of galactography for the diagnostic work-up of pathological nipple discharge in multimodal breast diagnostics : Part 1: An online survey among German breast care centers.]. Der Radiologe, . https://doi.org/10.1007/s00117-013-2572-8
Scheurlen, K, et al. "Stellenwert der Galaktographie zur Abklärung pathologischer Sekretion in der komplementären Mammadiagnostik : Teil 1: Eine Onlineumfrage an den deutschen Brustzentren." [Value of galactography for the diagnostic work-up of pathological nipple discharge in multimodal breast diagnostics : Part 1: An online survey among German breast care centers.]. Der Radiologe vol. (2013). doi: https://doi.org/10.1007/s00117-013-2572-8
Scheurlen K, Schnitzer A, Krammer J, Kaiser C, Schönberg SO, Wasser K. Stellenwert der Galaktographie zur Abklärung pathologischer Sekretion in der komplementären Mammadiagnostik : Teil 1: Eine Onlineumfrage an den deutschen Brustzentren. [Value of galactography for the diagnostic work-up of pathological nipple discharge in multimodal breast diagnostics : Part 1: An online survey among German breast care centers.]. Radiologe. 2013 Nov 15; doi: 10.1007/s00117-013-2572-8. Epub 2013 Nov 15. German. PMID: 24233401.
Copy Download .nbib Format: NLM
Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence.

The Journal of surgical research

O'Brien SJ, Scheurlen K, Rochet A, Fiechter C, Paas M, Pan J, Rai SN, Galandiuk S.
PMID: 34520983
J Surg Res. 2022 Jan;269:59-68. doi: 10.1016/j.jss.2021.08.004. Epub 2021 Sep 11.

BACKGROUND: Colon cancer is a leading cause of cancer-related death. Long non-coding (Lnc) RNAs are critical mediators of tumor biology. H19 is a well-characterized lncRNA involved in p53 regulation and cancer progression. A specific colon cancer data set was...

Cite
O'Brien SJ, Scheurlen K, Rochet A, et al. Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. J Surg Res. 2021;269:59-68doi: 10.1016/j.jss.2021.08.004.
O'Brien, S. J., Scheurlen, K., Rochet, A., Fiechter, C., Paas, M., Pan, J., Rai, S. N., & Galandiuk, S. (2022). Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. The Journal of surgical research, 26959-68. https://doi.org/10.1016/j.jss.2021.08.004
O'Brien, Stephen J, et al. "Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence." The Journal of surgical research vol. 269 (2022): 59-68. doi: https://doi.org/10.1016/j.jss.2021.08.004
O'Brien SJ, Scheurlen K, Rochet A, Fiechter C, Paas M, Pan J, Rai SN, Galandiuk S. Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. J Surg Res. 2022 Jan;269:59-68. doi: 10.1016/j.jss.2021.08.004. Epub 2021 Sep 11. PMID: 34520983.
Copy Download .nbib Format: NLM
Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma.

Cell death discovery

O'Brien SJ, Fiechter C, Burton J, Hallion J, Paas M, Patel A, Patel A, Rochet A, Scheurlen K, Gardner S, Eichenberger M, Sarojini H, Srivastava S, Rai S, Kalbfleisch T, Polk HC, Galandiuk S.
PMID: 33771981
Cell Death Discov. 2021 Mar 26;7(1):61. doi: 10.1038/s41420-021-00427-x.

Colon adenocarcinoma is a common cause of cancer-related deaths worldwide. Epithelial-mesenchymal transition is a major regulator of cancer metastasis, and increased understanding of this process is essential to improve patient outcomes. Long non-coding RNA (lncRNA) are important regulators of...

Cite
O'Brien SJ, Fiechter C, Burton J, et al. Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma. Cell Death Discov. 2021;7(1):61doi: 10.1038/s41420-021-00427-x.
O'Brien, S. J., Fiechter, C., Burton, J., Hallion, J., Paas, M., Patel, A., Patel, A., Rochet, A., Scheurlen, K., Gardner, S., Eichenberger, M., Sarojini, H., Srivastava, S., Rai, S., Kalbfleisch, T., Polk, H. C., & Galandiuk, S. (2021). Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma. Cell death discovery, 7(1), 61. https://doi.org/10.1038/s41420-021-00427-x
O'Brien, Stephen J, et al. "Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma." Cell death discovery vol. 7,1 (2021): 61. doi: https://doi.org/10.1038/s41420-021-00427-x
O'Brien SJ, Fiechter C, Burton J, Hallion J, Paas M, Patel A, Patel A, Rochet A, Scheurlen K, Gardner S, Eichenberger M, Sarojini H, Srivastava S, Rai S, Kalbfleisch T, Polk HC, Galandiuk S. Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma. Cell Death Discov. 2021 Mar 26;7(1):61. doi: 10.1038/s41420-021-00427-x. PMID: 33771981; PMCID: PMC7998025.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries